Kwiatkowski, David J.

Distribution of KRAS G12C Somatic Mutations across Race, Sex, and Cancer Type

Nassar, A. H., Adib, E., & Kwiatkowski, D. J. (2021) · New England Journal of Medicine

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 210

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Aisner, D. L., Sholl, L. M., Berry, L. D., Rossi, M. R., Chen, H., Fujimoto, J., Moreira, A. L., Ramalingam, S. S., Villaruz, L. C., Otterson, G. A., et al. (2018) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 206

Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex

Liang, N., Zhang, C., Dill, P., Panasyuk, G., Pion, D., Koka, V., Gallazzini, M., Olson, E. N., Lam, H., Henske, E. P., et al. (2014) · Journal of Experimental Medicine

Hippo pathway signaling and YAP/TAZTuberous Sclerosis Complex Research

Cited by 205

Tuberous Sclerosis Complex Activity Is Required to Control Neuronal Stress Responses in an mTOR-Dependent Manner

Di Nardo, A., Kramvis, I., Cho, N., Sadowski, A., Meikle, L., Kwiatkowski, D. J., & Sahin, M. (2009) · The Journal of Neuroscience

Tuberous Sclerosis Complex ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 165

Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex

Salussolia, C. L., Klonowska, K., Kwiatkowski, D. J., & Sahin, M. (2019) · Annual Review of Genomics and Human Genetics

Tuberous Sclerosis Complex ResearchEpilepsy research and treatment

Cited by 163

Cell‐specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers

Talos, D. M., Kwiatkowski, D. J., Cordero, K., Black, P. M., & Jensen, F. E. (2008) · Annals of Neurology

Tuberous Sclerosis Complex ResearchEpilepsy research and treatment

Cited by 156

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

Kwiatkowski, D. J., Rusch, V. W., Chaft, J. E., Johnson, B. E., Nicholas, A., Wistuba, I. I., Merritt, R., Lee, J. M., Bunn, P. A., Tang, Y., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 146

Association of machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images with outcomes of immunotherapy in patients with NSCLC

Rakaee, M., Adib, E., Ricciuti, B., Sholl, L. M., Shi, W., Alessi, J. V., Cortellini, A., Fulgenzi, C. A. M., Viola, P., Pinato, D. J., et al. (2023) · JAMA Oncology

Cancer Immunotherapy and BiomarkersAI in cancer detection

Cited by 141

Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2

Zhang, H., Fillmore Brainson, C., Koyama, S., Redig, A. J., Chen, T., Li, S., Gupta, M., Garcia-de-Alba, C., Paschini, M., Herter-Sprie, G. S., et al. (2017) · Nature Communications

Epigenetics and DNA MethylationCancer Cells and Metastasis

Cited by 127

Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors

Nassar, A. H., Adib, E., Abou Alaiwi, S., El Zarif, T., Groha, S., Akl, E. W., Nuzzo, P. V., Mouhieddine, T. H., Perea-Chamblee, T., Taraszka, K., et al. (2022) · Cancer Cell

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 121

Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin

Cheah, P.-S., Prabhakar, S., Yellen, D., Beauchamp, R. L., Zhang, X., Kasamatsu, S., Bronson, R. T., Thiele, E. A., Kwiatkowski, D. J., Stemmer-Rachamimov, A., et al. (2021) · Science Advances

Tuberous Sclerosis Complex ResearchVirus-based gene therapy research

Cited by 38

Identification of a region required for TSC1 stability by functional analysis of TSC1missense mutations found in individuals with tuberous sclerosis complex

Mozaffari, M., Hoogeveen-Westerveld, M., Kwiatkowski, D., Sampson, J., Ekong, R., Povey, S., den Dunnen, J. T., van den Ouweland, A., Halley, D., & Nellist, M. (2009) · BMC Medical Genetics

Tuberous Sclerosis Complex ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 36

Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target

Liu, Y., & Kwiatkowski, D. J. (2015) · Molecular Cancer Therapeutics

Bladder and Urothelial Cancer TreatmentsCancer-related Molecular Pathways

Cited by 35

Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma

Guo, Y., Chirieac, L. R., Bueno, R., Pass, H., Wu, W., Malinowska, I. A., & Kwiatkowski, D. J. (2014) · Oncogene

Occupational and environmental lung diseasesTGF-β signaling in diseases

Cited by 26